Related Experiment Video

Updated: Jan 18, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.1K

Advancing Oncology Drug Development in the US: The Interplay between Innovations and Regulatory Science

Yannan Nancy Dou1, Jian Wang2

  • 1Oncology Regulatory Science, Strategy & Excellence, AstraZeneca, Gaithersburg, MD, USA. yannandou@gmail.com.

Therapeutic Innovation & Regulatory Science
|May 22, 2025
PubMed

Insights

Innovation in cancer drug development is advancing rapidly. Regulatory science adapts to new technologies, ensuring safety and expediting patient access to novel therapies through collaboration.

Area of Science:

  • Oncology
  • Regulatory Science
  • Drug Development

Background:

  • The pharmaceutical industry is increasingly adopting novel therapeutic modalities, advanced technologies, and patient-focused clinical trial designs.
  • Cancer drug development is a dynamic field influenced by scientific breakthroughs and evolving regulatory frameworks.

Purpose of the Study:

  • To examine the relationship between innovation and regulatory science in the context of cancer drug development within the United States.
  • To understand how regulatory science accommodates emerging technologies and scientific insights.

Main Methods:

  • This study is a review of current trends and practices.
  • Analysis of the interplay between innovation and regulatory adaptation in cancer therapeutics.

Main Results:

  • Regulatory science evolves to incorporate new discoveries, maintaining safety and regulatory standards.
  • Innovation is fueled by regulatory adaptation, leading to expedited development and improved patient access.
  • Early and consistent communication between drug developers and regulatory bodies is crucial.

Conclusions:

  • The dynamic interaction between innovation and regulatory science accelerates the delivery of groundbreaking cancer treatments.
  • Proactive engagement with regulatory agencies is essential for successful navigation of innovative drug development pathways.
  • This synergy ultimately benefits patients by providing faster access to promising new therapies.
Keywords:
CancerDrug developmentFDAInnovationRegulatory science

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.8K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.1K

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.1K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
235
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
497